Results 81 to 90 of about 349,498 (354)
HYPERTENSION, 2019 The Ang II (Angiotensin II)-Angiotensin-(1-7) axis of the Renin Angiotensin System encompasses 3 enzymes that form Angiotensin-(1-7) [Ang-(1-7)] directly from Ang II: ACE2 (angiotensin-converting enzyme 2), PRCP (prolylcarboxypeptidase), and POP ...
P. Serfozo +11 more
semanticscholar +1 more source
Journal of the American Oil Chemists' Society, EarlyView.ABSTRACT The impressive growth in the global market for plant‐based foods has a direct impact on the food industry, requiring greater efforts in product reformulation for the replacement of animal‐based ingredients, including proteins. The replacement of animal‐derived proteins frequently applied as emulsifiers in food formulations, for example ...
Thais C. Brito‐Oliveira +2 more
wiley +1 more source
Frontiers in Physiology, 2014 Hypertension is a major risk factor for stroke, coronary events, heart and renal failure, and the renin-angiotensin system (RAS) plays a major role in its pathogenesis.
Sheila K Patel +7 more
doaj +1 more source
, 2021 Angiotensin converting enzyme (ACE) is well known for its dual actions to convert inactive Ang I to active Ang II, and degrades active bradykinin (BK), which plays an important role in controlling blood pressure. Because it is the bottleneck step for the production of pressor Ang II, it was targeted pharmacologically in the 1970s.
openaire +1 more source
Arthritis &Rheumatology, EarlyView.Objective The optimal treatment strategy for rheumatoid arthritis–associated interstitial lung disease (RA‐ILD) remains uncertain, and direct comparative data between biologics are limited. This study aimed to evaluate the effectiveness and safety of abatacept compared with rituximab in patients with RA‐ILD.
Po‐Cheng Shih +3 more
wiley +1 more source
RAMIPRIL IN THERAPY OF PATIENTS AFTER MYOCARDIAL INFARCTION
Рациональная фармакотерапия в кардиологии, 2015 Angiotensin converting enzyme inhibitors are the first line medicine for the treatment of the most of cardiovascular diseases. There is no class-effect for these drugs in myocardial infarction therapy.
I. V. Szirov, E. V. Malichenko
doaj +3 more sources
The Application of Clinical Genetics, 2019 Mohanad Yasir Al-Radeef,1 Hayder Adnan Fawzi,2 Ali Abdulmajid Allawi31Department of Clinical Pharmacy, College of Pharmacy, Tikrit University, Tikrit, Iraq; 2Department of Clinical Pharmacy, Baghdad Medical City Hospital, Baghdad, Iraq; 3Department of ...
Al-Radeef MY, Fawzi HA, Allawi AA
doaj
Angiotensin converting enzyme inhibitors and risk of lung cancer: population based cohort study
British medical journal, 2018 Objective To determine whether the use of angiotensin converting enzyme inhibitors (ACEIs), compared with use of angiotensin receptor blockers, is associated with an increased risk of lung cancer. Design Population based cohort study.
Blánaid M. Hicks +5 more
semanticscholar +1 more source
Arthritis &Rheumatology, Accepted Article.Objectives The aim of this study is to generate hypotheses about unknown drugs associated with the onset or worsening of Raynaud's Phenomenon (RP) and to explore their potential pathophysiological mechanisms through a mixed disproportionality/clustering analysis from the WHO pharmacovigilance database.
Alex Hlavaty +4 more
wiley +1 more source
Angiotensin‐converting enzyme inhibitors or angiotensin II receptor blockers and prognosis of hypertensive patients hospitalised with COVID‐19 [PDF]
, 2020 Marcello Covino +10 more
openalex +1 more source